302 related articles for article (PubMed ID: 30133174)
1. Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity.
Pauling JD; Reilly E; Smith T; Frech TM
Arthritis Care Res (Hoboken); 2019 Aug; 71(8):1119-1126. PubMed ID: 30133174
[TBL] [Abstract][Full Text] [Related]
2. Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis.
Pauling JD; Reilly E; Smith T; Frech TM
J Rheumatol; 2019 Oct; 46(10):1326-1334. PubMed ID: 30824643
[TBL] [Abstract][Full Text] [Related]
3. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
4. Construct validity and reliability of the Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) questionnaire.
Pauling JD; Yu L; Frech TM; Herrick AL; Hummers LK; Shah AA; Denton CP; Saketkoo LA; Withey J; Khanna D; Domsic RT
Rheumatology (Oxford); 2024 May; 63(5):1281-1290. PubMed ID: 37481713
[TBL] [Abstract][Full Text] [Related]
5. Raynaud's phenomenon-an update on diagnosis, classification and management.
Pauling JD; Hughes M; Pope JE
Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
[TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.
Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
Clin Rheumatol; 2022 Oct; 41(10):3049-3054. PubMed ID: 35583625
[TBL] [Abstract][Full Text] [Related]
7. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.
Pauling JD; Frech TM; Hughes M; Gordon JK; Domsic RT; Anderson ME; Ingegnoli F; McHugh NJ; Johnson SR; Hudson M; Boin F; Ong VH; Matucci-Cerinic M; Altorok N; Scolnik M; Nikpour M; Shah A; Pope JE; Khanna D; Herrick AL
J Scleroderma Relat Disord; 2018 Oct; 3(3):249-252. PubMed ID: 30705970
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
[TBL] [Abstract][Full Text] [Related]
10. Raynaud's phenomenon and its impact on activities in daily life during one year of follow-up in early systemic sclerosis.
Sandqvist G; Wollmer P; Scheja A; Wildt M; Hesselstrand R
Scand J Rheumatol; 2018 May; 47(3):206-209. PubMed ID: 28803485
[TBL] [Abstract][Full Text] [Related]
11. Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.
Pauling JD; Domsic RT; Saketkoo LA; Almeida C; Withey J; Jay H; Frech TM; Ingegnoli F; Dures E; Robson J; McHugh NJ; Herrick AL; Matucci-Cerinic M; Khanna D; Hewlett S
Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1373-1384. PubMed ID: 29473715
[TBL] [Abstract][Full Text] [Related]
12. Domain reporting in systemic sclerosis-related Raynaud's phenomenon: An OMERACT scoping review.
Maltez N; Hughes M; Brown E; Hickey V; Shea B; Herrick AL; Proudman S; Merkel PA; Pauling JD
Semin Arthritis Rheum; 2023 Aug; 61():152208. PubMed ID: 37202251
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
14. Factors Influencing Patient Decision-Making Concerning Treatment Escalation in Raynaud's Phenomenon Secondary to Systemic Sclerosis.
Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
Arthritis Care Res (Hoboken); 2021 Dec; 73(12):1845-1852. PubMed ID: 34057304
[TBL] [Abstract][Full Text] [Related]
15. Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary.
Pauling JD; Shipley JA; Hart DJ; McGrogan A; McHugh NJ
J Rheumatol; 2015 Jul; 42(7):1163-8. PubMed ID: 26034146
[TBL] [Abstract][Full Text] [Related]
16. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
Ingegnoli F; Carmona L; Castrejon I
Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
[TBL] [Abstract][Full Text] [Related]
19. Raynaud's phenomenon.
Herrick AL; Wigley FM
Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101474. PubMed ID: 32007400
[TBL] [Abstract][Full Text] [Related]
20. The patient experience of Raynaud's phenomenon in systemic sclerosis.
Pauling JD; Saketkoo LA; Matucci-Cerinic M; Ingegnoli F; Khanna D
Rheumatology (Oxford); 2019 Jan; 58(1):18-26. PubMed ID: 29538754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
